

Supplementary References

1. Li X, Wei LC, Zhang Y, Zhao LN, Li WW, Ping LJ, et al. The prognosis and risk stratification based on pelvic lymph node characteristics in patients with locally advanced cervical squamous cell carcinoma treated with concurrent chemoradiotherapy. *Int J Gynecol Cancer* 2016;26:1472-9.
2. Shim SH, Lee SW, Park JY, Kim YS, Kim DY, Kim JH, et al. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy. *Gynecol Oncol* 2013;128:54-9.
3. Kang S, Nam BH, Park JY, Seo SS, Ryu SY, Kim JW, et al. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean Gynecologic Oncology Group Study. *J Clin Oncol* 2012;30:2369-74.
4. Tseng JY, Yen MS, Twu NF, Lai CR, Horng HC, Tseng CC, et al. Prognostic nomogram for overall survival in stage IIB-IVA cervical cancer patients treated with concurrent chemoradiotherapy. *Am J Obstet Gynecol* 2010;202:174.e1-7.
5. Liang JA, Chen SW, Chang WC, Hung YC, Yeh LS, Yang SN, et al. Risk stratification for failure in patients with advanced cervical cancer after concurrent chemoradiotherapy: another way to optimise treatment results. *Clin Oncol (R Coll Radiol)* 2008;20:683-90.
6. Polterauer S, Grimm C, Hofstetter G, Concin N, Natter C, Sturdza A, et al. Nomogram prediction for overall survival of patients diagnosed with cervical cancer. *Br J Cancer* 2012;107:918-24.
7. Kidd EA, El Naqa I, Siegel BA, Dehdashti F, Grigsby PW. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. *Gynecol Oncol* 2012;127:136-40.
8. Rose PG, Java J, Whitney CW, Stehman FB, Lanciano R, Thomas GM, et al. Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. *J Clin Oncol* 2015;33:2136-42.
9. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group Study. *J Clin Oncol* 1999;17:1339-48.

10. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. *N Engl J Med* 1999;340:1144-53.
11. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med* 1999;340:1154-61.
12. Lanciano R, Calkins A, Bundy BN, Parham G, Lucci JA 3rd, Moore DH, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2005;23:8289-95.
13. Thomas G, Ali S, Hoebbers FJ, Darcy KM, Rodgers WH, Patel M, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. *Gynecol Oncol* 2008;108:317-25.
14. DiSilvestro PA, Ali S, Craighead PS, Lucci JA, Lee YC, Cohn DE, et al. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group Study. *J Clin Oncol* 2014;32:458-64.
15. Therneau TM, Grambsch PM. Modeling survival data: extending the cox model. New York (NY): Springer Science & Business Media; 2000.
16. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. *J Clin Epidemiol* 2013;66:648-53.
17. Austin PC, Lee DS, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. *Circulation* 2016;133:601-9.